{"id":290864,"date":"2026-10-07T09:18:31","date_gmt":"2026-10-07T03:48:31","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=290864"},"modified":"2026-10-07T09:18:31","modified_gmt":"2026-10-07T03:48:31","slug":"generic-pharma-exporter-stocks-strong-roadmap","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/generic-pharma-exporter-stocks-strong-roadmap\/","title":{"rendered":"3 Generic Pharma Exporter Stocks With a Strong Future Roadmap: Strides Pharma Science, Granules India and Marksans Pharma"},"content":{"rendered":"

Strides Rs 1,088.70, P\/E 15.80. Granules India Rs 836.40, P\/E 34.44. Marksans Pharma Rs 324.40, P\/E 28.20. Closing prices of 6 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Generic pharma exporter stocks with the clearest long-term roadmaps today include Strides Pharma Science in generic formulations for regulated markets, mainly the United States, Granules India in paracetamol, active ingredients and finished dosage forms and Marksans Pharma in over-the-counter products and generic formulations for the United Kingdom and United States. FY26 revenue growth was 8.3% at Strides, 19.8% at Granules India and 12.8% at Marksans Pharma. P\/E stands at 15.80 for Strides (industry 37.19), 34.44 for Granules India (industry 37.19) and 28.20 for Marksans Pharma (industry 37.19). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Generic pharma exporter stocks give investors exposure to Indian makers that supply low-cost medicines to regulated markets abroad. Results depend on product approvals, pricing in export markets and plant compliance, which is why margins and cash flow matter as much as headline growth.<\/p>\n

This list covers three US generics stocks: Strides Pharma Science for generic formulations for regulated markets, mainly the United States, Granules India for paracetamol, active ingredients and finished dosage forms and Marksans Pharma for over-the-counter products and generic formulations for the United Kingdom and United States. Every figure comes from the latest reported financials and the 6 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n